Genus plc (LSE:GNS) reported a stronger-than-anticipated first-half performance for its 2026 financial year, with adjusted profit before tax, excluding a milestone payment, now expected to be around £50 million. Including the milestone, adjusted profit is forecast at approximately £55.6 million, both figures ahead of internal expectations. The outperformance reflects robust trading at the PIC pork genetics division alongside in-line results from the ABS cattle genetics business.
On the back of this momentum, the board has upgraded its full-year outlook, now expecting adjusted profit before tax, excluding the milestone, to come moderately above the top end of current market forecasts. The update points to continued strength in Genus’s core operations and improving earnings visibility across its global genetics portfolio.
Genus also confirmed that China’s State-owned Assets Supervision and Administration Commission (SASAC) has approved the establishment of its porcine joint venture in China. This regulatory clearance triggers a final US$7.5 million milestone payment from joint venture partner BCA, with completion of the transaction and receipt of funds expected in the third quarter of the current financial year. The development marks a significant step in Genus’s strategy to expand its presence in the Chinese pork market and strengthens its long-term growth prospects in a key global protein sector.
From an investment perspective, Genus’s outlook is supported by positive corporate developments and solid financial delivery. However, technical indicators point to potential overbought conditions, while a relatively high P/E ratio suggests valuation may already reflect much of the near-term optimism.
More about Genus plc
Genus plc is a global leader in animal genetics, applying advanced biotechnology to improve livestock breeding outcomes. The Group supplies high-value genetic products to dairy, beef and pork producers in more than 75 countries through its ABS (cattle) and PIC (pigs) brands. Its offerings include semen, embryos and breeding animals designed to enhance productivity, efficiency and quality across global protein supply chains, supported by proprietary breeding lines, an extensive distribution network and innovations such as its PRRS-resistant pig, which is progressing through further regulatory approvals ahead of wider commercial rollout.
Leave a Reply